The anti-arthritic activity of Panzem (2-methoxyestradiol, or 2ME2) was evaluated in a preclinical animal model of rheumatoid arthritis. Data from the study demonstrated that oral treatment with 2ME2
Avigen has already secured one funding source for its Parkinson’s disease program and is actively exploring additional options to fund its other AAV development activities. The decision to
The first trial site is the Dana-Farber Cancer Institute in Boston. The primary objective of the phase I/II dose escalation study is to evaluate the safety of GCS-100LE
The multi-center phase II study is being conducted according to a two-stage Simon trial design, in which the primary objective must be met in the first stage of
The collaboration will evaluate RNA interference (RNAi)-based therapeutic formulations in immune cells from patients with rheumatoid arthritis (RA) for the purpose of selecting a candidate for preclinical and
“We are very pleased to advance ZIO-101 as our second compound in clinical development and to have met our timeline,” commented Dr Mark Thornton, head of product development
The goal of this initiative is to reduce the frequency and duration of dosing. Ventavis (iloprost) is marketed by CoTherix in the US for the treatment of pulmonary
According to terms of the agreement, Lorus will provide Sumitomo proprietary antisense oligonucleotides complementary to Thioredoxin mRNA, specifically the lead drug candidate, GTI-2601. The collaboration agreement provides for
These findings have been highlighted in a report carried out by the House of Commons Health Committee. In the report, the committee stated that UK regulatory authority the
A licensing agreement was signed between the two companies in March this year, granting Gilead the exclusive rights to Japan Tobacco’s novel HIV integrase inhibitor, JTK-303, in all
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.